Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. | Available online http content 6 3 R264 Research article Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment Francesca Bobbio-Pallavicini1 Claudia Alpini2 Roberto Caporali1 Stefano Avalle2 Serena Bugatti1 and Carlomaurizio Montecucco1 Department of Rheumatology University of Pavia IRCCS Policlinico S. Matteo Pavia Italy 2Clinical Chemistry Laboratories University of Pavia IRCCS Policlinico S. Matteo Pavia Italy Corresponding author Francesca Bobbio-Pallavicini francescabobbio@ Received 22 Jan 2004 Revisions requested 10 Feb 2004 Revisions received 27 Feb 2004 Accepted 09 Mar 2004 Published 26 Apr 2004 Arthritis Res Ther 2004 6 R264-R272 DOI ar1173 2003 Bobbio-Pallavicini et al. licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Open Access Abstract The aim of the present study was to investigate the effect of long-term infliximab treatment on various autoantibodies in patients with rheumatoid arthritis. Serum samples from 30 consecutive patients who were prospectively followed during infliximab and methotrexate therapy for refractory rheumatoid arthritis were tested at baseline and after 30 54 and 78 weeks. At these points median values of the Disease Activity Score were interquartile range and respectively. Various autoantibodies were assessed by standard indirect immunofluorescence and or ELISA. Initially 50 of patients were positive for antinuclear antibodies and this figure increased to 80 after 78 weeks P . A less marked similar increase was found for IgG and IgM anticardiolipin antibody titre whereas the frequency of anti-double-stranded DNA antibodies by ELISA exhibited a transient rise up to at 54 weeks and dropped to 0 at 78 weeks. Antibodies to
